Wellcome Sanger researchers released an updated NanoSeq method that adapts duplex sequencing for targeted panels, offering a lower‑cost approach to profile rare somatic variants across hundreds of samples. The revision enables affordable detection of low‑frequency, 'pre‑oncogenic' mutations in genes of interest and supports large‑cohort studies of mutational processes. The work complements other advances in high‑sensitivity genomic tools that aim to map early mutational events and improve molecular surveillance in cancer research.